Experienced commercial leader brings 20 years of experience in pharma Princeton, N.J., October 5, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Drayton T. Virkler to the newly created position of Chief Commercial Officer. In this role, Mr. Virkler will drive the Company’s global commercial strategy and … Continued
Complementary technologies accelerate and help assure success in the drug development process Princeton, N.J., October 4, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the completion of the previously announced transaction to acquire Pinnacle 21, a leading provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness. … Continued
Streamline developing a summary of changes for an Investigator’s Brochure, a document that summarizes the clinical and nonclinical data on an investigational drug.
PRINCETON, N.J.— September 13, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold … Continued
PRINCETON, N.J.—September 8, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its common stock by Certara and certain existing stockholders (“the selling stockholders”) at a price to the public of $31.00 per share. Certara is offering 4.5 million shares of its … Continued
PRINCETON, N.J.—September 3, 2021. Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering 4,500,000 shares of common stock and certain selling stockholders are offering 15,500,000 shares … Continued
PRINCETON, N.J.— August 31, 2021 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences: Morgan Stanley 19th Annual Global Healthcare ConferenceDate and Time: Tuesday, September 14 at 9:30 a.m. ETSpeakers: William Feehery, chief executive officer, and Andrew … Continued
PRINCETON, N.J.— August 24, 2021. Certara, the global leader in biosimulation, today announced the appointments of Terri Madison, Ph.D. as Senior Vice President and General Manager of Evidence and Access, Heather Valentine as Senior Vice President of Software Sales and Marketing, and Ron DiSantis as Senior Vice President of Corporate Development. These new appointments will … Continued
Raises full year 2021 guidance and announces deal to acquire Pinnacle 21 PRINCETON, N.J.—August 5, 2021– Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2021. Highlights: Revenue was $70.1 million, representing growth of 15% over the second quarter of 2020 Net loss … Continued
Princeton, N.J., July 27, 2021: Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara. The investment aligns with Mubadala’s strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies. Mubadala and certain existing institutional shareholders of Certara, including … Continued
